Company Overview of Quanterix Corporation
Quanterix Corporation develops and provides ultra-sensitive diagnostic platform for measuring individual proteins. The company offers Single Molecule Array technology that enables the detection and quantification of biomarkers in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more; assay kits; and consumables. Its products are used in life science research, oncology, neurology, inflammatory disease, and infectious disease applications. Quanterix Corporation was formerly known as Digital Genomics Inc. and changed its name to Quanterix Corporation in August 2007. The company was founded in 2007 and is based in Lexington, Massachusetts.
13 Hartwell Avenue
Lexington, MA 02421
Founded in 2007
Key Executives for Quanterix Corporation
Chief Financial Officer and Vice President of Finance and Administration
Chief Technology Officer and Vice President of Research
Compensation as of Fiscal Year 2013.
Quanterix Corporation Key Developments
Quanterix Receives Three New Patents for Simoa Platform
Oct 22 13
Quanterix Corporation has received three new patents for its Simoa platform. Two of the patents, which are at the foundation of the Simoa technology, are assigned to Tufts University and exclusively licensed to Quanterix. The third patent is a result of Quanterix's own innovation, which takes the Simoa technology a step further by combining digital and analog signal measurements, allowing a broad dynamic range of concentrations that can be measured. The result enables the detection and quantification of biomarkers previously difficult or impossible to measure. These new patents demonstrate the remarkable innovation at the core of Simoa technology, which provides researchers with the ability to detect biomarkers at concentrations 1,000 times lower than possible now. This in turn opens up new applications to address significant unmet needs in life science research, biopharma, and in-vitro diagnostics.
Quanterix Corporation Appoints Paul Meister as Board of Director
Aug 15 13
Quanterix Corporation announced the appointment of Paul Meister to its Board of Directors. Mr. Meister is the co-founder of Liberty Lane Partners, LLC. He also previously served as Chairman of the Board of Thermo Fisher Scientific Inc. and Vice Chairman of Fisher Scientific International Inc. Mr. Meister is also Co-Chair of the University of Michigan's Life Sciences Institute External Advisory Board and serves on the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University.
Quanterix Announces Availability of Simoa Single Molecule Array Technology
Jul 30 13
Quanterix Corporation unveiled its Single Molecule Array (Simoa) technology at the 2013 AACC Annual Meeting in Houston, Texas, making it commercially available for the first time on a fully automated platform for research use only. With Simoa, life science researchers will be empowered to explore biomarkers and pathways with greater sensitivity and precision, paving the way for the development of new diagnostic tests and improved treatment of diseases in oncology, neurology, cardiology, and other fields of medicine. Simoa provides the ability to detect, measure and validate both new and existing biomarkers easily and cost effectively at concentrations previously unattainable. As a result of studies conducted while the technology was in beta testing, Simoa has already fueled promising discoveries in the following studies: Prostate Cancer – Simoa’s sensitivity to minute PSA levels after radical prostatectomy provides a reliable predictor of disease recurrence with important implications for PSA testing frequency and selection of candidates for adjuvant therapy1. Crohn’s Disease – Simoa provides the first quantitative measurements of TNF- and IL-6 concentrations in the plasma of all patients with Crohn’s disease, which offers promise in helping to monitor therapeutic efficacy. Alzheimer’s Disease – Using Simoa, researchers were able for the first time to demonstrate that Amyloid-beta 42 levels in blood acutely rise after an ischemic episode, and that the concentration levels were reliable predictors of outcome as it relates to neurological function. Simoa’s remarkable sensitivity and fully automated productivity advantage are competitively priced to fit into laboratory environment. Features include: Ultrasensitivity – 1,000-fold improvement over present immunoassays. Precision – Exceptional robustness and repeatability at ultra-low concentrations of target proteins. Full Automation – With an intuitive touch screen interface to program a few basic parameters, users receive complete results in as soon as 30 minutes. Wide Dynamic Range – Proprietary combination of both digital and analog signal measurements provides >4 logs of dynamic range. Easy and Cost-Effective Implementation – Using low cost immunoassay reagents and consumables, the analyzer can be economically deployed and quickly integrated into an existing laboratory. Multiplexing Capability – Up to 10 different analyses can be tested in a single assay. Throughput – The instrument has a processing speed of 80 samples/hour, yielding up to 800 results/hour for a 10-plex.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|